Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.02.010Source: DataRank Database

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer is a research paper published in Clinical Genitourinary Cancer (2023). On theSindex it has a DataRank of 0. It has been cited 58 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access58 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 9.26)OA: greenTopics (30)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Michael T. Schweizer ORCID,Kim N.ORCID,Rahul Aggarwal ORCID,Neeraj Agarwal ORCID,James L. Gulley ORCID

Live enrichment

PubMed:36948922 OpenAlex:https://openalex.org/W4328095977

Intramural NIH HHS

Grant: Z99 CA999999

FWCI

9.26

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10219845/pdf/nihms-1878575.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1558767323000435?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1558767323000435?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10219845

Fields of Study

Prostate Cancer Treatment and ResearchImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersMaleHumansProstatic Neoplasms, Castration-ResistantProstate-Specific AntigenTreatment OutcomeAntineoplastic AgentsTumor Microenvironment

MeSH Terms

Antineoplastic AgentsHumansMaleTreatment OutcomeProstate-Specific AntigenTumor MicroenvironmentProstatic Neoplasms, Castration-Resistant

Keywords

MedicineProstate cancerInternal medicineAndrogen deprivation therapyOncologyCancerImmunotherapyProstateCancer researchCytokine release syndromeDose escalationImmunosuppressionPSA

Sustainable Development Goals

SDG 0: Good health and well-being